Zyagnum is a biotechnology company with the goal of making serious diseases visible and thus treatable at the earliest possible stage. We are convinced that many diseases can be treated and cured better the earlier they are detected. Therefore, we believe that the key to curing the major unsolved medical problems of our time lies in early detection diagnostics.
Since 2007, we have been working with our long-established core team and close partners to develop technologies that can detect these common diseases earlier. The result of this intensive development period is our proprietary EDIM® Technology.
With approx. 50 employees at the Darmstadt site as well as numerous close business partners in Germany and abroad, we are now working on the implementation of our ideas for diagnostics.
Zyagnum is a biotechnology company with the goal of making serious diseases visible and thus treatable at the earliest possible stage. We are convinced that many diseases can be treated and cured better the earlier they are detected. Therefore, we believe that the key to curing the major unsolved medical problems of our time lies in early detection diagnostics.
Since 2007, we have been working with our long-established core team and close partners to develop technologies that can detect these common diseases earlier. The result of this intensive development period is our proprietary EDIM® Technology.
With more than 30 employees at the Darmstadt site as well as numerous close business partners in Germany and abroad, we are now working on the implementation of our ideas for diagnostics.
We are convinced that the earliest possible detection of diseases is the prerequisite for the best possible treatments and optimal chances of recovery.
That is why we are driven by the vision of making chronic health imbalances diagnosable even before the disease can manifest itself. This is the prerequisite for turning the early detection of life-changing diseases such as cancer, Alzheimer’s or diabetes into true prevention.
Our aim is to make our diagnostics as simple, cost-effective, and burden-free as possible so that as many people as possible can benefit from them.
We are convinced that the earliest possible detection of diseases is the prerequisite for the best possible treatments and optimal chances of recovery.
That is why we are driven by the vision of making chronic health imbalances diagnosable even before the disease can manifest itself. This is the prerequisite for turning the early detection of life-changing diseases such as cancer, Alzheimer’s or diabetes into true prevention.
Our aim is to make our diagnostics as simple, cost-effective, and burden-free as possible so that as many people as possible can benefit from them.
Read more about the innovative EDIM-Technologie
Based on a unique discovery, we aim to usher in a new era in the early detection of serious diseases.
In the following years, Zyagnum added the additional parameter DNaseX (Apo10) to the test. This indicates that the programmed death of cancer cells (apoptosis) is disrupted.
PanTum Detect® is officially approved as a medical product in the EU.
Ralf Schierl
Founder & CEO
Hendrik Krämer
CFO / Head of Finance & Sales
Anette Ludwig
COO
Dr. Oliver Feyen
CSO (Chief Scientific Officer)